CN101988113A - In-situ hybridization detection kit for DCC genes and detection method and application thereof - Google Patents

Abstract

The invention relates to an in-situ hybridization detection kit for DCC (deleted in colorectal cancer) genes, which comprises a hybridization probe and a marker, wherein the sequence of the hybridization probe is expressed as SEQ ID No.1. The invention also provides an in-situ hybridization detection method for the DCC genes. In addition, the invention also provides application of the kit in preparing a medicament for detecting gastric cancer or pancreatic cancer diseases. The kit provided by the invention has the advantages of high sensitivity and strong specificity. The detection method is convenient and simple for operation, and can be universally used and popularized in hospitals of above district level.

Description

A kind of hybridization in situ detection kit of DCC gene and detection method thereof and application

[technical field]

The present invention relates to a kind of test kit, specifically about a kind of hybridization in situ detection kit and detection method and application of DCC gene

[background technology]

Carcinoma of the pancreas has become one of ten big malignant tumours of China human mortality.Young carcinoma of the pancreas patient is also than the trend that was significantly increased before 10 years, and grade of malignancy is higher, and prognosis is poorer.With regard to the happening part of carcinoma of the pancreas, see at most with the head of pancreas position that still account for about 70%, body of pancreas takes second place, tail of pancreas portion more takes second place, and a body afterbody that has all has, and belongs to diffuse lesion or multicentricity pathology.At present, the pathogenic factor of carcinoma of the pancreas it be unclear that, and has found that some environmental factorss are relevant with the generation of carcinoma of the pancreas.Wherein fixed primary Hazard Factor are smoking.The carcinoma of the pancreas relative risk takes place the smoker is 1.5 times of non-smoker, and along with amount of smoking increases and increases.Other high-risk factors also have diabetes, chololithiasis, drink (comprising beer) and chronic pancreatitis etc.Take food higher fatty acid, high protein diet and purified flour foods, 20 years persons after the gastrectomy also are that risk factor for pancreatic cancer takes place.Carcinoma of the pancreas lethality extra-high-speed, how possibility surreptitious concealment because it is fallen ill has entered event in late period when making a definite diagnosis.

Cancer of the stomach is one of China's common malignancy, in the first place that its sickness rate of China occupies all kinds of tumours.The incidence gastric cancer rate of China is with take second place East China and have 170,000 people to die from cancer of the stomach approximately coastal Central-South the and southwestern minimum every year of taking second place again of the highest northeast, northwest and the Inner Mongol, almost near 1/4 of whole malignant tumour death tolls, and annual also have that new Patients with Gastric Cancer generates more than 20,000, and cancer of the stomach is a kind of disease of serious threat people's health really.

DCC gene (deleted in colorectal cancer) is positioned at karyomit(e) 18q21.3, it is present in most of healthy tissuess, its product is one group of glycoprotein, effect with surface receptor, its structure is similar to cell adhesion molecule, may be the cell signalling acceptor, its disappearance can make tumour cell rise in value rapidly, and the someone thinks that it is the cancer suppressor gene.Unusual most of late phase that occur in tumour of DCC gene, DCC genetically deficient may be by influencing invasion and attack and the transfer that cell-cell adhesion mechanism causes tumour.In the research of cancer of the stomach, discovery DCC genetically deficients such as Bamias disappearance is more common in differentiation difference and signet ring cell cancer person, thinks that DCC genetically deficient is the independent Invasion and Metastasis predictor of cancer of the stomach.Hohne etc. studies show that in low differentiation or do not break up DCC expression extreme minimizing or disappearance in the carcinoma of the pancreas

Along with molecular biotechnology is perfect day by day, functional genomics, the deep expansion of research such as cancer genomics, so far, we might do more accurate early diagnosis on gene level, form the early prediction diagnosis that (during mono-clonal) just can accomplish gene level in canceration early stage or cancer cells.The present invention adopts nucleic acid hybridization in situ technology for detection DCC gene, and the diagnosis of early gene levels such as carcinoma of the pancreas and cancer of the stomach is had very important clinical meaning.DCC gene order number: NM_005215,5690bp, mRNA, 18q21.3 ", cds:588 ... 4931bp.

Hybridization in situ technique of the present invention (in situ hybridization) combines molecular biology and cytochemistry technology, is probe with the nucleic acid molecule of mark, in the technology of histocyte in situ detection specific nucleic acid molecule.Its principle is to make the nucleic acid strand (being probe) that contains distinguished sequence, process mark, under optimum conditions with histocyte in the complementary nucleic acid strand be that target nucleic acid is hybridized, with radioautograph or immunocytochemistry label probe is surveyed again, thereby shown special DNA or RNA molecule at cell in-situ.

[summary of the invention]

The objective of the invention is provides a kind of purposes of hybridization in situ detection kit of DCC gene at deficiency of the prior art.

One purpose more of the present invention is that a kind of hybridization in situ detection kit of DCC gene is provided.

Another purpose of the present invention is that a kind of in situ hybridization detection method of DCC gene is provided.

For achieving the above object, the technical scheme taked of the present invention is:

The application of a kind of hybridization in situ detection kit of DCC gene in preparation detection cancer of the stomach or carcinoma of the pancreas disease medicament, described test kit comprises hybridization probe, marker, described hybridization probe sequence is shown in SEQ ID NO.1.

The RNA sequence of described hybridization probe sequence shown in SEQ ID NO.1.

Described marker is selected from radionuclide or non-radioactive marker.

Described radionuclide is selected from ³H, ³⁵S, ¹²⁵I or ³²A kind of among the P.

Described non-radioactive marker is selected from a kind of in vitamin H, digoxin, alkaline phosphatase, horseradish peroxidase or the fluorescein.

Described non-radioactive marker is preferably from digoxin.

Described test kit also comprises synergistic agent, and described synergistic agent is the alkaline phosphatase enzyme antibody.

For realizing above-mentioned second purpose, the technical scheme that the present invention takes is:

A kind of hybridization in situ detection kit of DCC gene comprises hybridization probe, marker, and wherein said hybridization probe sequence is shown in SEQ ID NO.1, and described marker is selected from radionuclide or non-radioactive marker.

For realizing above-mentioned the 3rd purpose, the technical scheme that the present invention takes is:

A kind of in situ hybridization detection method of DCC gene, this method may further comprise the steps:

A, the hybridization probe in the test kit is contacted with RNA to be measured in the substrate, form hybridization complex;

The hybridization complex that b, detection a step obtain.

The condition that forms hybridization complex in the described a step is: the temperature of nucleic acid hybridization is 42 ℃; The time of nucleic acid hybridization is 16-24 hour, and described substrate is selected blood cell sample or histocyte sample for use.

The component of diagnostic kit of the present invention is by hybridization probe, hybridization solution, developer, compositions such as synergistic agent.The nucleic acid hybridization principle of this test kit is that the molecular biology insider all knows, and the concrete operations step is to carry out quantitative analysis, result's report under sample disposal, prehybridization, hybridization, immunohistochemical staining, the mirror, and wherein Za Jiao concrete steps comprise:

Instrumentation:

1). sample to be measured is put into reactive tank;

2). instrument discards liquid automatically, adds Digestive system automatically;

3). instrument discards liquid automatically, and the back is fixing automatically;

4). instrument discards liquid automatically, automatically prehybridization (42 ℃);

5). instrument discards liquid automatically, cleans automatically;

6). instrument discards liquid automatically, automatically hybridization (42 ℃);

7). instrument discards liquid automatically, cleans automatically;

8). instrument discards liquid automatically, and automatic and DIG antibody is cultivated (room temperature);

9). instrument discards liquid automatically, cleans colour developing automatically;

10). take out the mounting microscopy.

The invention has the advantages that:

1, test kit provided by the invention has characteristics highly sensitive, high specificity.

2, detection method of the present invention is convenient and simple for operation, can be widely used and promoted in Municipal Hospitals.

3, clinical meaning of the present invention is that more early stage tracking detects cancer of the stomach or carcinoma of the pancreas generation dynamic process, and the detection and the screening implement that are used for cancer of the stomach or carcinoma of the pancreas preventive medicine.Diagnostic kit of the present invention is with other detects the oncofetal protein mark clinically, and the medical imaging inspection has remarkable difference.The present invention can detect the DCC unconventionality expression on gene level, before medical imaging inspection and other inspection is not found occupancy cancer of the stomach or carcinoma of the pancreas focus, before the cancer biochemical indicator does not produce unusually, also do not form before the lump, the information acquisition of above abnormal gene expression be can accomplish early, clinical cancer of the stomach or real prognosis early diagnosis of carcinoma of the pancreas sufferer given.So just might implement early diagnosis, early prevention, the early treatment of cancer of the stomach or carcinoma of the pancreas, might from the source, thoroughly effect a radical cure cancer of the stomach or carcinoma of the pancreas foul disease.

[description of drawings]

Fig. 1 is a carcinoma of the pancreas patient DCC genetic expression picture in the embodiment of the invention.

Fig. 2 is a Patients with Gastric Cancer DCC genetic expression picture in the embodiment of the invention.

Fig. 3 is a normal people DCC genetic expression picture in the embodiment of the invention.

[embodiment]

Below in conjunction with accompanying drawing the specific embodiment of the invention is elaborated.

Embodiment 1

A kind of hybridization in situ detection kit of DCC gene comprises hybridization probe, marker, synergistic agent, and wherein, described hybridization probe sequence is shown in SEQ ID NO.1.The hybridization probe digoxigenin labeled.Other liquid and sample in the test kit are composed as follows:

Digestive system 100 μ l/ manage 1 pipe/box colourless transparent liquid

Protection liquid 100 μ l/ pipe 1 pipe/box colourless transparent liquid

Prehybridization solution 1300 μ l/ manage 2 pipe/box colourless transparent liquids

Justice hybridization solution 10 μ l/ pipe 1 pipe/box colourless transparent liquid

Antisense hybridization solution 10 μ l/ manage 1 pipe/box colourless transparent liquid

Confining liquid 1000 μ l/ manage 1 pipe/box colourless transparent liquid

Alkaline phosphatase enzyme antibody 1 μ l/ manages 1 pipe/box colourless transparent liquid

Developer A 175 μ l/ manage 1 pipe/box yellow liquid

Developer B 320 μ l/ manage 1 pipe/box colourless transparent liquid

Light yellow or the colourless transparent liquid of damping fluid I10x 90ml/ bottle 1 bottle/box

Light yellow or the colourless transparent liquid of damping fluid II 10x 80ml/ bottle 1 bottle/box

Light yellow or the colourless transparent liquid of damping fluid III 10x 20m/ bottle 3 bottle/boxes

Light yellow or the colourless transparent liquid of damping fluid IV 10x 90ml/ bottle 1 bottle/box

Stationary liquid 90ml/ bottle 1 bottle/box colourless transparent liquid

6/box of positive control sample

Mentioned reagent composition explanation: (all reagent are available from SIGMA)

1, Digestive system: the 20mg/ml Proteinase K, the 100mg Proteinase K adds DEPC-H ₂O 5ml;

2, the glycine of protection liquid: 0.2g adds 1 * damping fluid I of 1ml;

3, prehybridization solution: 1 * damping fluid II7.5ml

50×D?3ml

10mg/ml?yest?t-RNA?750ul

11mg/ml?SALMON?TESTES?DNA 682ul

0.04M?EDTA?3ml

50％formamide?15ml

4, the bloking of confining liquid: 0.03g (buying from Roche Holding Ag) adds 1ml 1 * damping fluid III;

5,10x damping fluid I:(PH7.1-7.4)

NaCl?80g

Na ₂HPO ₄.12H ₂O 360g

KCl 2g

KH ₂PO ₄2g

Add tri-distilled water to 1l, and autoclaving;

6,10x damping fluid II:(PH7.0)

NaCl 175.3g

Trisodium Citrate 88.2g

Several of HCl

Add tri-distilled water to 1l, and autoclaving;

7, damping fluid III:(PH7.9)

Tris 121.1g

NaCl 87.66g

About HCl 60ml

Add tri-distilled water to 1l, and autoclaving;

8, damping fluid IV:

1M Tris-HCl (PH9.5): Tirs 121.1g adds about HCl 3ml, adds water 900ml, transfers PH to 9.5, adds water to 1l, and autoclaving;

1M NaCl:NaCl 58.44 adds water to 1l, and autoclaving;

0.5M MgCl ₂: 101.65g MgCl ₂.6H ₂O adds water to 1l, and autoclaving;

9, stationary liquid: Paraformaldehyde 96 40g adds 1 * damping fluid I to 1l, and heat (about 50-60 degree) is stirred to dissolving a little;

10, developer A:NBT 1g adds 70%DMF11.44ml;

11, developer B:BCIP 1g adds 100%DMF30ml.

Test kit of the present invention can many person-portions use or person-portion use.

Embodiment 2

A kind of DCC gene hybridization in situ detection method and test kit thereof are used

One, sample disposal

1, with the centrifuge tube of 10ml, dress 4.5ml lymphocyte separation medium, again the 3ml anticoagulation is slowly added contain lymphocyte separation medium (blood: in centrifuge tube lymphocyte separation medium=1: 1.5), the centrifugal 10min of 2000r/min;

2, draw the middle layer white corpuscle to another centrifuge tube, in this pipe, add 1 * damping fluid I of about twice again, mixing, the centrifugal 10min of 1500g/min;

3, abandon supernatant. precipitation adds 1 * damping fluid I of about twice, mixing, the centrifugal 10min of 1500g/min;

4, abandon supernatant, and test tube mouth excess liquid is gone with the tissue suction.Again precipitation is made suspension, drop in push jack on the slide, seasoning.(hospital with good conditionsi can use the pelleter film-making.) 3ml blood, can do 4 slice, thin pieces;

5, with 40ml 4% stationary liquid, in glass jar, fixedly 30min uses 1 * damping fluid I to wash 5min again.Every cylinder can be put 16;

6, sample can be kept at-20 ℃, or continues to do experiment.

Two, reagent in the test kit is mixed with working concentration

1, with 10 * damping fluid I with tri-distilled water by being diluted to 1 * damping fluid I at 1: 10;

2, with 20 * damping fluid II with tri-distilled water by being diluted to 2 * damping fluid II at 1: 10;

By being diluted to 0.2 * damping fluid II at 1: 100; By being diluted to 0.1 * damping fluid II at 1: 200;

3, with 10 * damping fluid III with tri-distilled water by being diluted to 1 * damping fluid III at 1: 10;

4,10 * damping fluid IV with tri-distilled water by be diluted at 1: 10 * damping fluid IV (get 1#, 2#, each 10ml of 3#, add water to 100ml both can).

Three, experimental procedure:

1, gets two of every person's samples to be checked, two of (other two give over to check with) and positive control samples (test at every turn and do a pair of positive control);

2, in glass jar, add Digestive system (Digestive system 100ul adds 1 * damping fluid 199.9ml, is working concentration) 20ml.37 ℃ of water-bath preheatings 10 minutes.Put 16 slides into, handle 12min, use 1 * damping fluid I to wash 5min again for 37 ℃;

3, wash 10min with 0.2% protection liquid (protection liquid 1ml adds 1 * damping fluid I99ml and is working concentration), tri-distilled water is washed 5min, and above process is all carried out at glass jar.The slide seasoning;

4, slide is put into the box of preserving moisture, add prehybridization solution 20ul/ sheet. covered, the lid box of tightly preserving moisture is placed in 42 ℃ of constant water bath box more than the 3h;

5, take out slide, discard cover glass, slide is put into glass jar, with 70%, 90%, 95% ethanol is respectively washed 2min, seasoning;

6, slide is put into the box of preserving moisture, two of every patient specimens, one adds just hybridization solution 20ul/ sheet, and another adds antisense hybridization solution 20ul/ sheet, covered, the lid box of tightly preserving moisture is placed on 16-24h in 42 ℃ of constant water bath box;

7, take out slide, discard cover glass, slide is put into glass jar

In 42 ℃ of constant water bath box, wash twice, each 15min with 2 * damping fluid II

In 42 ℃ of constant water bath box, wash once each 15min with 0.2 * damping fluid II

In 42 ℃ of constant water bath box, wash twice, each 15min with 0.1 * damping fluid II;

8, wash 30s with 1 * damping fluid III, take out slide, seasoning;

9, slide is put into the box of preserving moisture, add 0.5%l confining liquid (the 1ml confining liquid adds 5ml 1 * damping fluid III) 100ul/ sheet, cover the box of tightly preserving moisture, at room temperature act on 30min;

10, take out slide, III washes 30s with 1 * damping fluid, seasoning;

11, slide is put into the box of preserving moisture, add alkaline phosphatase enzyme antibody (adding 1.8ml 1 * damping fluid III) 100ul/ sheet, cover the box of tightly preserving moisture and at room temperature act on 30min;

12, take out slide, wash 3 times, each 15min with 1 * damping fluid III;

13,1 * damping fluid IV washes 2min, adds developer (developer A73.3ul, developer B157.5ul are added among 30ml 1 * damping fluid IV, mixing), more than the room temperature lucifuge 12h;

14, wash 5min with tri-distilled water, seasoning, (add with glycerine 10% 1 * damping fluid I mixing) mounting microscopy.

Four, the result judges

100-300 cell of counting calculates the per-cent of catching the purple cell under light microscopic.

What the positive control sample added the antisense hybridization solution should catch purple more than 80%.

All add the negative internal reference of just hybridization solution should be colourless.

The cDNA of digoxigenin labeled, RNA and oligonucleotide probe, not only probe has a biotin labeling advantage, also having overcome biotin labeled probe is organized the endogenous vitamin H to do shortcomings such as sorrow in the crossover process in position), this hybridization probe and the leukocytic RNA nucleic acid to be measured of blood of human body are hybridized, method with immunohistochemical methods develops the color again, under light microscopic, observe existence and the location of mRNA,, judge the expression amount of goal gene according to painted cell count.

The inventive method is a nucleic acid hybridization in situ technology commonly used at present, and this method is used for determining the prognosis of cancer by detecting the DCC gene expression amount in the substrate cell.Clinical study shows, the DCC gene is low the expression in cancer, because the DCC gene is at normal people's high expression level, and the low expression explanation cancer of DCC gene, DCC expression of gene degree is relevant with the prognosis of cancer, belongs to negative correlation, expresses that more to hang down prognosis poorer.Thereby obtain the diagnostic message of cancer.As mentioned above, when detecting DCC genetic expression, measurable experimenter is a cancerous condition.

The embodiment of the invention is sampled as: 5 of Patients with Gastric Cancer, 5 of carcinoma of the pancreas patients, 5 of normal control groups.Take out all people's to be checked peripheral blood 3-5 milliliter (separation white corpuscle) and do in situ hybridization.The result represents that all cancer patients DCC genes are not expressed the cell dye-free.Normal control group DCC has overexpression, cell dyeing.Concrete outcome is asked for an interview Fig. 1, Fig. 2 and Fig. 3.

The above only is a preferred implementation of the present invention; should be pointed out that for those skilled in the art, under the prerequisite that does not break away from the inventive method; can also make some improvement and replenish, these improvement and replenish and also should be considered as protection scope of the present invention.

SEQUENCE?LISTING

＜110〉Rui bends biotechnology (Shanghai) Co., Ltd.

＜120〉a kind of hybridization in situ detection kit of DCC gene and detection method thereof and application

<130>/

<160>1

<170>PatentIn?version?3.3

<210>1

<211>5690

<212>DNA

＜213〉homo sapiens (Homo sapiens)

<400>1

accgctggcg?gacaccccag?taacaagtga?gagcgctcca?ccccgcagtc?ccccccgcct 60

ctcctccctg?ggtcccctcg?gctctcggaa?gaaaaaccaa?cagcatctcc?agctctcgcg 120

cggaattgtc?tcttcaactt?tacccaaccg?acgacaagga?accagcctca?accttttaat 180

gcacagcccg?gccacaggat?tgccttccat?ctcctcttgg?tccctcctgg?atgtggttta 240

ttgatgactt?gcgagcccct?cagagagctg?tcttccctcc?tctggctccc?tccgtttcct 300

tgagttagtt?ttctaaggtt?ttaccggggc?tcgggatctc?ttggaccgaa?tggaactttt 360

tgctgcctgc?ttttgctgct?gattctgtca?gtggacaagg?aaaaaggctt?cgaaggcagc 420

agaggcgcag?gggaggtgga?gaaagaggtg?gaggaagagg?acgaggagga?ggaggaagcc 480

gaaggggctc?ggcgcgtgtg?tgtgcatgtg?tgcatgcgtg?tgtgagtgca?tgtgtgtgag 540

tgctgccgct?gcccgcgacc?cctggccccg?aaggtgttgg?ctgaaatatg?gagaatagtc 600

ttagatgtgt?ttgggtaccc?aagctggctt?ttgtactctt?cggagcttcc?ttgttcagcg 660

cgcatcttca?agtaaccggt?tttcaaatta?aagctttcac?agcactgcgc?ttcctctcag 720

aaccttctga?tgccgtcaca?atgcggggag?gaaatgtcct?cctcgactgc?tccgcggagt 780

ccgaccgagg?agttccagtg?atcaagtgga?agaaagatgg?cattcatctg?gccttgggaa 840

tggatgaaag?gaagcagcaa?ctttcaaatg?ggtctctgct?gatacaaaac?atacttcatt 900

ccagacacca?caagccagat?gagggacttt?accaatgtga?ggcatcttta?ggagattctg 960

gctcaattat?tagtcggaca?gcaaaagttg?cagtagcagg?accactgagg?ttcctttcac 1020

agacagaatc?tgtcacagcc?ttcatgggag?acacagtgct?actcaagtgt?gaagtcattg 1080

gggagcccat?gccaacaatc?cactggcaga?agaaccaaca?agacctgact?ccaatcccag 1140

gtgactcccg?agtggtggtc?ttgccctctg?gagcattgca?gatcagccga?ctccaaccgg 1200

gggacattgg?aatttaccga?tgctcagctc?gaaatccagc?cagctcaaga?acaggaaatg 1260

aagcagaagt?cagaatttta?tcagatccag?gactgcatag?acagctgtat?tttctgcaaa 1320

gaccatccaa?tgtagtagcc?attgaaggaa?aagatgctgt?cctggaatgt?tgtgtttctg 1380

gctatcctcc?accaagtttt?acctggttac?gaggcgagga?agtcatccaa?ctcaggtcta 1440

aaaagtattc?tttattgggt?ggaagcaact?tgcttatctc?caatgtgaca?gatgatgaca 1500

gtggaatgta?tacctgtgtt?gtcacatata?aaaatgagaa?tattagtgcc?tctgcagagc 1560

tcacagtctt?ggttccgcca?tggtttttaa?atcatccttc?caacctgtat?gcctatgaaa 1620

gcatggatat?tgagtttgaa?tgtacagtct?ctggaaagcc?tgtgcccact?gtgaattgga 1680

tgaagaatgg?agatgtggtc?attcctagtg?attattttca?gatagtggga?ggaagcaact 1740

tacggatact?tggggtggtg?aagtcagatg?aaggctttta?tcaatgtgtg?gctgaaaatg 1800

aggctggaaa?tgcccagacc?agtgcacagc?tcattgtccc?taagcctgct?atcccaagct 1860

ccagtgtcct?cccttcggct?cccagagatg?tggtccctgt?cttggtttcc?agccgatttg 1920

tccgtctcag?ctggcgccca?cctgcagaag?cgaaagggaa?cattcaaact?ttcacggtct 1980

ttttctccag?agaaggtgac?aacagggaac?gagcattgaa?tacaacacag?cctgggtccc 2040

ttcagctcac?tgtgggaaac?ctgaagccag?aagccatgta?cacctttcga?gttgtggctt 2100

acaatgaatg?gggaccggga?gagagttctc?aacccatcaa?ggtggccaca?cagcctgagt 2160

tgcaagttcc?agggccagta?gaaaacctgc?aagctgtatc?tacctcacct?acctcaattc 2220

ttattacctg?ggaaccccct?gcctatgcaa?acggtccagt?ccaaggttac?agattgttct 2280

gcactgaggt?gtccacagga?aaagaacaga?atatagaggt?tgatggacta?tcttataaac 2340

tggaaggcct?gaaaaaattc?accgaatata?gtcttcgatt?cttagcttat?aatcgctatg 2400

gtccgggcgt?ctctactgat?gatataacag?tggttacact?ttctgacgtg?ccaagtgccc 2460

cgcctcagaa?cgtctccctg?gaagtggtca?attcaagaag?tatcaaagtt?agctggctgc 2520

ctcctccatc?aggaacacaa?aatggattta?ttaccggcta?taaaattcga?cacagaaaga 2580

cgacccgcag?gggtgagatg?gaaacactgg?agccaaacaa?cctctggtac?ctattcacag 2640

gactggagaa?aggaagtcag?tacagtttcc?aggtgtcagc?catgacagtc?aatggtactg 2700

gaccaccttc?caactggtat?actgcagaga?ctccagagaa?tgatctagat?gaatctcaag 2760

ttcctgatca?accaagctct?cttcatgtga?ggccccagac?taactgcatc?atcatgagtt 2820

ggactcctcc?cttgaaccca?aacatcgtgg?tgcgaggtta?tattatcggt?tatggcgttg 2880

ggagccctta?cgctgagaca?gtgcgtgtgg?acagcaagca?gcgatattat?tccattgaga 2940

ggttagagtc?aagttcccat?tatgtaatct?ccctaaaagc?ttttaacaat?gccggagaag 3000

gagttcctct?ttatgaaagt?gccaccacca?ggtctataac?cgatcccact?gacccagttg 3060

attattatcc?tttgcttgat?gatttcccca?cctcggtccc?agatctctcc?acccccatgc 3120

tcccaccagt?aggtgtacag?gctgtggctc?ttacccatga?tgctgtgagg?gtcagctggg 3180

cagacaactc?tgtccctaag?aaccaaaaga?cgtctgaggt?gcgactttac?accgtccggt 3240

ggagaaccag?cttttctgca?agtgcaaaat?acaagtcaga?agacacaaca?tctctaagtt 3300

acacagcaac?aggcctcaaa?ccaaacacaa?tgtatgaatt?ctcggtcatg?gtaacaaaaa 3360

acagaaggtc?cagtacttgg?agcatgactg?cacatgccac?cacgtatgaa?gcagccccca 3420

cctctgctcc?caaggacttg?acagtcatta?ctagggaagg?gaagcctcgt?gccgtcattg 3480

tgagttggca?gcctcccttg?gaagccaatg?ggaaaattac?tgcttacatc?ttattttata 3540

ccttggacaa?gaacatccca?attgatgact?ggattatgga?aacaatcagt?ggtgataggc 3600

ttactcatca?aatcatggat?ctcaaccttg?atactatgta?ttactttcga?attcaagcac 3660

gaaattcaaa?aggagtgggg?ccactctctg?atcctatcct?cttcaggact?ctgaaagtgg 3720

aacaccctga?caaaatggct?aatgaccaag?gtcgtcatgg?agatggaggt?tattggccag 3780

ttgatactaa?tttgattgat?agaagcaccc?taaatgagcc?gccaattgga?caaatgcacc 3840

ccccgcatgg?cagtgtcact?cctcagaaga?acagcaacct?gcttgtgatc?attgtggtca 3900

ccgttggtgt?catcacagtg?ctggtagtgg?tcatcgtggc?tgtgatttgc?acccgacgct 3960

cttcagccca?gcagagaaag?aaacgggcca?cccacagtgc?tggcaaaagg?aagggcagcc 4020

agaaggacct?ccgaccccct?gatctttgga?tccatcatga?agaaatggag?atgaaaaata 4080

ttgaaaagcc?atctggcact?gaccctgcag?gaagggactc?tcccatccaa?agttgccaag 4140

acctcacacc?agtcagccac?agccagtcag?aaacccaact?gggaagcaaa?agcacctctc 4200

attcaggtca?agacactgag?gaagcaggga?gctctatgtc?cactctggag?aggtcgctgg 4260

ctgcacgccg?agccccccgg?gccaagctca?tgattcccat?ggatgcccag?tccaacaatc 4320

ctgctgtcgt?gagcgccatc?ccggtgccaa?cgctagaaag?tgcccagtac?ccaggaatcc 4380

tcccgtctcc?cacctgtgga?tatccccacc?cgcagttcac?tctccggcct?gtgccattcc 4440

caacactctc?agtggaccga?ggtttcggag?caggaagaag?tcagtcagtg?agtgaaggac 4500

caactaccca?acaaccacct?atgctgcccc?catctcagcc?tgagcattct?agcagcgagg 4560

aggcaccaag?cagaaccatc?cccacagctt?gtgttcgacc?aactcaccca?ctccgcagct 4620

ttgctaatcc?tttgctacct?ccaccaatga?gtgcaataga?accgaaagtc?ccttacacac 4680

cacttttgtc?tcagccaggg?cccactcttc?ctaagaccca?tgtgaaaaca?gcctcccttg 4740

ggttggctgg?aaaagcaaga?tcccctttgc?ttcctgtgtc?tgtgccaaca?gcccctgaag 4800

tgtctgagga?gagccacaaa?ccaacagagg?attcagccaa?tgtgtatgaa?caggatgatc 4860

tgagtgaaca?aatggcaagt?ttggaaggac?tcatgaagca?gcttaatgcc?atcacaggct 4920

cagcctttta?acatgtattt?ctgaatggat?gaggtgaatt?ttccgggaac?tttgcagcat 4980

accaattacc?cataaacagc?acacctgtgt?ccaagaactc?taaccagtgt?acaggtcacc 5040

catcaggacc?actcagttaa?ggaagatcct?gaagcagttc?agaaggaata?agcattcctt 5100

ctttcacagg?catcaggaat?tgtcaaatga?tgattatgag?ttccctaaac?aaaagcaaag 5160

atgcattttc?actgcaatgt?caaagtttaa?gctgctagaa?tagtcatggg?cctttgtcac 5220

tgcagtgacc?acactgtcat?aactaatacc?tatgttttcc?tttgtcaagg?cctgttgttt 5280

aatgtgtagg?tctagtctta?caaaatgcaa?gtgcattatt?taagcctgta?ccatgccatg 5340

gcaaaccagt?gcaagctcac?tattttgttt?tcaacttaaa?catacaaagc?acccatggga 5400

atctctcatg?ccatagcacc?aaaggattgg?atgttttcct?tacagcacaa?aaagtaaata 5460

gtaaacaaac?aaaaggcaga?gaatgcttat?gtttgtaact?cagtcattca?tcttgcacaa 5520

gtggtggata?ttagtgagtg?gctaaaaatt?cacctatttt?ggcaagtatt?tgtaaatcca 5580

cccttggtta?atatgtatgt?ctggagtcca?ggaatataaa?aatctgcaac?tagtggcatt 5640

ctgccagcag?cagtacattt?ctggaaagag?gatataatat?gcaatcttct 5690

Claims (10)

1. the application of the hybridization in situ detection kit of a DCC gene in preparation detection cancer of the stomach or carcinoma of the pancreas disease medicament, described test kit comprises hybridization probe, marker, described hybridization probe sequence is shown in SEQ ID NO.1.

2. application according to claim 1 is characterized in that: the RNA sequence of described hybridization probe sequence shown in SEQ ID NO.1.

3. application according to claim 1 and 2 is characterized in that: described marker is selected from radionuclide or non-radioactive marker.

4. application according to claim 3 is characterized in that: described radionuclide is selected from ³H, ³⁵S, ¹²⁵I or ³²A kind of among the P.

5. application according to claim 3 is characterized in that: described non-radioactive marker is selected from a kind of in vitamin H, digoxin, alkaline phosphatase, horseradish peroxidase or the fluorescein.

6. application according to claim 5 is characterized in that: described non-radioactive marker is preferably from digoxin.

7. application according to claim 1 and 2 is characterized in that: described test kit also comprises synergistic agent, and described synergistic agent is the alkaline phosphatase enzyme antibody.

8. the hybridization in situ detection kit of a DCC gene comprises hybridization probe, marker, it is characterized in that, described hybridization probe sequence is shown in SEQ ID NO.1, and described marker is selected from radionuclide or non-radioactive marker.

9. the in situ hybridization detection method of a DCC gene is characterized in that, this method may further comprise the steps:

A, the hybridization probe in the described test kit of claim 8 is contacted with RNA to be measured in the substrate, form hybridization complex;

The hybridization complex that b, detection a step obtain.

10. detection method according to claim 9 is characterized in that: the condition that forms hybridization complex in a step is: the temperature of nucleic acid hybridization is 42 ℃; The time of nucleic acid hybridization is 16-24 hour, and described substrate is selected blood cell sample or histocyte sample for use.

Images